Mice deficient for dopamine D 2 and D 3 receptors exhibit blunted c-fos responses to D 1 agonist stimulation. Stereologic cell counting revealed decreased numbers of medial prefrontal cortex neurons that express Fos immunoreactivity in all layers, particularly in the prelimbic and anterior cingulate subregions. Pretreatment of these mutants with a single, low dose of methamphetamine (METH) led to a sustained increase in the number of neurons that express Fos immunoreactivity in response to a D 1 agonist challenge, which was most significant in prelimbic and anterior cingulate subregions. The increased c-fos responses reached wild-type-like levels in METH-pretreated D 2 mutants but remained submaximal in METH-pretreated D 3 mutants. Additional studies tested the performance of wild type and mutants in a delayed alternation test, a cognitive task critically dependent on optimal activation of prefrontal cortical D 1 receptors by synaptically released dopamine. Both D 2 and D 3 mutants exhibited deficits in their spatial working memory, with increasing impairments at increasing delays. Whereas METH pretreatment rescued the spatial working memory of D 2 mutants, it had no effect on D 3 mutants. These data suggest that the sustained improvement of spatial working memory in METH-pretreated D 2 mutants is attributable to D 1 receptormediated mechanisms.
Mice deficient for dopamine D 2 and D 3 receptors exhibit blunted c-fos responses to D 1 agonist stimulation. Stereologic cell counting revealed decreased numbers of medial prefrontal cortex neurons that express Fos immunoreactivity in all layers, particularly in the prelimbic and anterior cingulate subregions. Pretreatment of these mutants with a single, low dose of methamphetamine (METH) led to a sustained increase in the number of neurons that express Fos immunoreactivity in response to a D 1 agonist challenge, which was most significant in prelimbic and anterior cingulate subregions. The increased c-fos responses reached wild-type-like levels in METH-pretreated D 2 mutants but remained submaximal in METH-pretreated D 3 mutants. Additional studies tested the performance of wild type and mutants in a delayed alternation test, a cognitive task critically dependent on optimal activation of prefrontal cortical D 1 receptors by synaptically released dopamine. Both D 2 and D 3 mutants exhibited deficits in their spatial working memory, with increasing impairments at increasing delays. Whereas METH pretreatment rescued the spatial working memory of D 2 mutants, it had no effect on D 3 mutants. These data suggest that the sustained improvement of spatial working memory in METH-pretreated D 2 mutants is attributable to D 1 receptormediated mechanisms.
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The prefrontal cortex (PFC) is a set of neocortical areas involved in temporary storage of information (short-term or working memory) and the implementation of executive processes needed for voluntary, goal-directed behavior (for review, see Miller, 1999 Miller, , 2000 Smith and Jonides, 1999; Fuster, 2001) . In humans, the effects of lesions of the PFC are most apparent under test conditions that require cognitive control (Miller, 2000) , and working memory deficits have also been documented for dopaminedepleted rhesus monkeys (Brozoski et al., 1979) . The latter observation gave rise to the conclusion that a decrease in prefrontal cortical dopaminergic neurotransmission is also responsible for the working memory deficits seen in patients with Parkinson's disease (Gotham et al., 1988; Levin et al., 1989) and schizophrenia (Weinberger et al., 1986; Fukushima et al., 1988; Park and Holzman, 1992) and in children at high risk for schizophrenia (Erlenmeyer-Kimling et al., 2000) .
Working memory requires activation of prefrontal cortical dopamine D 1 receptors (Williams and Goldman-Rakic, 1995) . Although studies have shown that the D 1 receptor dependence is a "U-shaped" function and that normal cognitive function requires the optimal activation of D 1 receptors (Williams and GoldmanRakic, 1995; Zahrt et al., 1997) , more recent studies point to the importance of an intricately balanced activity of D 1 and D 2 -like receptors (D 2 , D 3 , and D 4 ). For example, Castner et al. (2000) showed that monkeys chronically treated with a neuroleptic drug known to block D 2 -like receptors exhibit impaired working memory, and molecular studies on knock-out mice deficient for D 2 and D 3 receptors revealed a decreased agonist-stimulated D 1 receptor activity in the forebrain Schmauss, 2000) despite unaltered expression of D 1 receptor radioligand binding sites in such mutants (Baik et al., 1995; Xu et al., 1997) . Moreover, a single dose of either a full D 1 agonist or methamphetamine (METH) (Schmauss, 2000) or intermittent D 1 agonist stimulation (Castner et al., 2000) led to a sustained rescue of the deficits described in these studies.
To explore further the roles of D 2 and D 3 receptors in modulating D 1 receptor activation in the PFC, the present study investigated agonist-stimulated D 1 receptor activity in D 2 and D 3 receptor knock-out mice . We performed quantitative immunocytochemical studies to analyze prefrontal cortical c-fos responses to a systemically administered D 1 agonist and behavioral studies to test the performance of the mutants in a spatial working memory task. The results revealed significantly blunted D 1 agonist-stimulated c-fos responses in the PFC of both mutants. Moreover, both mutants exhibit significant deficits in spatial working memory. A single dose of METH rescues the blunted prefrontal cortical c-fos responses in D 2 mutants but has only a partial effect in D 3 mutants. METH also rescues the spatial working memory deficits of D 2 mutants. The impaired working memory of D 3 mutants, however, is unaffected by METH.
MATERIALS AND METHODS

Animals.
All experiments were performed with the fifth generation of homozygous, congenic C57BL /6 D 2 and D 3 mutants and their wild-type littermates. The generation of the mutant mice is described by . For all studies, male mice at postnatal day 60 (P60) to P90 were used. Animals were group housed and had access to food and water ad libitum unless otherwise indicated. All procedures involving the animals were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laborator y Animals and were approved by the Institutional Animal C are and Use committees at Columbia University and the New York State Psychiatric Institute.
Drugs. All drugs were dissolved in saline and injected intraperitoneally. The D 1 agonists SK F82958 and SK F81297 (administered at 1 and 2 mg / kg, respectively) and S-methamphetamine (5 mg / kg) were purchased from Sigma (St. L ouis, MO).
R NA e xtraction and Northern blotting. Animals were decapitated, their brains were rapidly removed, and the forebrain was dissected as described by Schmauss (2000) . In some experiments, additional dissections of the anterior 4 mm of the forebrain (frontal cortex) were performed. RNA was extracted using guanidine -cesium chloride ultracentrif ugation. Ten micrograms of total RNA were loaded onto 1.2% formaldehyde -agarose gels and transferred to nylon membranes. Membranes were hybridized to a 32 P-radiolabeled, random-primed 540-nucleotide-long mouse c-fos cDNA as described previously (Schmauss, 2000) .
In situ hybridization. Sixteen-micrometer-thick cryosections of Freon-frozen brains of wild type and D 2 / D 3 double mutants were thaw mounted onto gelatin-coated slides, dried for 2 min at 37°C, and then refrozen at Ϫ80°C. Each slide contained sections of wild type and D 2 / D 3 double mutants that were collected at similar interaural coordinates. In situ hybridizations were performed as described previously (Schmauss et al., 1992) , and c-fos mRNA was hybridized to a 35 Slabeled antisense riboprobe (1 ϫ 10 6 cpm /300 l) comprising 540 nucleotides of the mouse c-fos mRNA (Schmauss, 2000) . Air-dried slides were exposed to Kodak MR film (Eastman Kodak, Rochester, N Y) for 14 hr. Images on film were digitized using the microcomputer imaging device (MCI D) image analysis system (Imaging Research, St. C atharines, Ontario, C anada) and colorized uniformly to highlight c-fos signal intensities.
Immunoc ytochemistr y and stereolog ical anal ysis. The expression of Fos immunoreactivity was analyzed in 16 m cryosections and in 40 m microtome sections obtained from brains of drug-naive and M ETHpretreated wild type and D 2 and D 3 single mutants. Slide-mounted cryosections of fresh-frozen brains were postfixed (10 min in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4) immediately after sectioning and processed as described below. Microtome sections (freefloating) were obtained from immersion-fixed brains (6 hr in the fixative described above) and used exclusively for stereological analysis. After fixation, nonspecific staining was reduced by incubating sections for 5 min in hydrogen peroxide [0.3% in 0.1 M Tris-buffered saline (TBS), pH 7.6], and then for 30 min in TBS containing 0.5% bovine serum albumin (BSA). Incubations with primary antibody were performed overnight at room temperature in 0.1% BSA and 0.25% Triton X-100 in TBS. A rabbit polyclonal anti-c-fos antibody (Ab-5; 1:7500; Oncogene Sciences, Boston, M A) was used to detect Fos immunoreactivity. Adjacent sections of immersion-fixed tissues were also incubated with a mouse monoclonal antibody directed against tyrosine hydroxylase (1:5000; Diasorin, Stillwater, M N) or a mouse monoclonal anti-neuronal-specific nuclear protein (NeuN) antibody (1:10,000; Chemicon, Temecula, CA). After incubation with primary antibody, sections were incubated for 30 min with biotinylated goat anti-rabbit or goat anti-mouse IgG (1:400 in TBS containing 0.1% BSA; Vector Laboratories, Burlingame, CA), followed by a 30 min incubation in avidin -biotin -peroxidase complex (Vectastain Elite kit; 1:100 in TBS; Vector Laboratories). Bound immunoperoxidase was visualized by incubation for 6 min in 0.022% 3,3Ј-diaminobenzidine (Aldrich, Milwaukee, W I) and 0.003% hydrogen peroxide in TBS. Sections were rinsed in TBS between incubations and in 0.1 M phosphate buffer at the end of staining. Free-floating sections were mounted onto gelatin-coated slides and lightly counterstained in 0.25% thionin. For photographic purposes, images were captured digitally at 4 and 10ϫ magnification using a SPOT camera (Diagnostic Instruments, Sterling Heights, M I).
To obtain a quantitative estimate of the numbers of nuclei expressing the Fos protein in the PFC of wild type and D 2 and D 3 single mutants and to test whether differences exist between the three genotypes in the numbers of neurons or glia, a stereologic counting method was used. For this analysis, a Z eiss (Oberkochen, Germany) Axioplan 2 photomicroscope equipped with a Dage-MTI (Michigan C ity, I N) DC -330 CCD camera and L ud1 motorized stage and interfaced with a Gateway Athlon computer and StereoInvestigator (MicroBrightField, Colchester, V T) were used.
The stereologic analysis was conducted on brain sections obtained from five to nine drug-naive and M ETH-pretreated animals per genotype. For each case, three adjacent series of 40-m-thick sections, collected at an intraseries interval of 200 m, were used. These series were processed to label the following: (1) Fos immunoreactivity in thionin-counterstained sections, (2) NeuN immunoreactivity, or (3) tyrosine hydroxylase immunoreactivity. The latter two series were used to identif y the boundaries between layers II / III and V/ V I. Total numbers of neurons, glia, and Fos-positive nuclei were determined in three subregions, the infralimbic (IL), prelimbic (PL), and anterior cingulate (AC) cortices in three (IL) or six (PL and AC) sections from the series, using an unbiased stereologic method, the optical fractionator (West et al., 1991) . Thus, a total of six regions (layers II / III and layers V/ V I of IL, PL, and AC) were analyzed. Neurons and glia were identified using morphological criteria that characterize the nuclei of both cell types (Vaughan, 1984; Peters et al., 1991) . Optical dissector frames and counting grid sizes of 30 and 100 m 2 , respectively, were chosen to permit systematic random sampling of three to five neurons within an 8 m focusing range for each sampling field and 200 -600 neurons for each region. These parameters allowed for intrasample coefficients of error (CE), calculated as described previously (Schmitz and Hof, 2000) , that averaged 0.06 Ϯ 0.01 for neurons and 0.08 Ϯ 0.01 for glia and Fos-labeled nuclei for all regions. There were no significant differences in CE values across genotypes or treatment groups. All regions were sampled at high magnification in Koehler illumination conditions using a Z eiss 63ϫ Plan-Apochromate objective. The number of Fos-labeled neurons was subsequently expressed as a percentage of the total number of neurons counted within each region. The volume of the different laminar domains of interest in each of the three PFC regions was estimated using the C avalieri principle. For statistical analysis of the stereologic data, a one-way ANOVA (threshold of significance, ␣ ϭ 0.05) was performed, and significance of differences were analyzed post hoc by a Student's t test.
Spatial delayed alternation. For these experiments, the body weight of the animals was gradually reduced (over a period of 10 -14 d) until the animals reached 80% of their individual starting body weight. During the entire course of the experiments, their body weights were monitored daily to adjust the amount of food (Prolab Isopro RM H 3000; PM I Nutrition, Brendwood, MO) provided (usually 2.5 gm /animal per day).
Delayed alternation tests were performed using a T-maze designed for rodents. The maze was constructed from 0.6-cm-thick Plexiglas. Its main alley (58 ϫ 11 ϫ 18.5 cm) was connected to two side arms (30 ϫ 11 ϫ 18.5 cm), which contained sliding doors used to close off the arms manually. Small dishes containing food pellets were positioned at the end of these arms. A holding box (13 ϫ 11 ϫ 18.5 cm) contained a manually operated sliding door used to close off the entrance to the main alley of the T-maze.
E xperiments were performed with 32 animals and conducted in two series. In one series, eight homozygous D 3 mutants were tested in parallel with eight wild-type littermates, and, in the other series, eight D 2 mutants were tested in parallel with eight wild-type animals. At the end of the gradual weight reduction period, mice were exposed for 3 consecutive days to the T-maze, which had both arms open, and baited with food (one mouse at a time). Then, the mice were subjected to a 3 d period of "forced alternation runs," i.e., one arm was closed off and the food reward was positioned in the other (open) arm (Verma and Moghaddam, 1996) . Next, animals were trained at a 5 sec retention time, allowing 11 trials of continuous alternation per day with both arms open. In the first run, animals were allowed to explore both arms until they found the food pellet located in one of them. In the following 10 trials, they were rewarded only for the alternate (correct) selection of arms. After each arm entry (correct or incorrect), animals remained in the arm for 12 sec and were then placed back into the holding box. The training period ended after wild-type animals made Ͼ70% correct choices on 2 consecutive days. In both series of experiments, all wild-type animals reached this criterion. Animals were then tested for their performance at 15, 20, or 30 sec delay periods.
In all experiments, the T-maze was located in the same position so that potential spatial cues never changed. All experiments were performed between 1:00 P.M. and 4:30 P.M. A statistical comparison of data were performed by an ANOVA, and significant main effects were analyzed f urther by post hoc comparisons of means using the Bonferroni's multiple comparisons test.
RESULTS
Blunted c-fos mRNA responses to dopamine D 1 agonists in mice deficient for D 2 and D 3 receptors
The induction of expression of the immediate-early gene c-fos is a sensitive indicator of neuronal activity stimulated by D 1 agonists. Previous results of RNA and protein studies indicate that knock-out mice deficient for dopamine D 2 and D 3 receptors exhibit blunted forebrain c-fos responses to administration of the full D 1 agonist SKF82958 Schmauss, 2000) . As shown in Figure 1 , forebrain c-fos mRNA expression induced by SKF82958 is critically dependent on D 1 receptor expression. D 1 knock-out mice (generated by Drago et al., 1994) fail to exhibit c-fos mRNA responses to this drug. As further shown in Figure 1 , blunted c-fos mRNA responses of both mutants are also detected with another full D 1 agonist, SKF81297, and, consistent with results of a previous study that used SKF82958 (Schmauss, 2000) , the blunted c-fos responses to SKF81297 treatment can also be reversed in a long-term manner by a single dose of METH. Thus, the results shown in Figure 1 , as well as results of studies using SKF82958 in wild-type animals pretreated with a D 2 -like antagonist , indicate that SKF82958 has no agonist effects on D 2 -like receptors. A more detailed characterization of the basal and SKF82958-stimulated forebrain c-fos mRNA expression levels of drug-naive and METH-pretreated wild type and D 2 and D 3 mutants can be found elsewhere (Schmauss, 2000) .
A single dose of METH (5 mg/kg) results in a long-term reversal of the blunted D 1 receptor activity in both D 2 and D 3 single mutants (Schmauss, 2000) . To test whether METH pretreatment can also reverse the blunted c-fos mRNA responses of homozygous D 2 /D 3 double mutants, we performed in situ hybridization experiments using forebrain sections of wild type and double mutants that contained the PFC. As shown in Figure 2 , SKF82958-stimulated expression of c-fos mRNA is prominent in wild type and appears highest in PL and IL cortices, as well as in deeper layers of the AC cortex. In corresponding anatomic regions of drug-naive D 2 /D 3 double mutants, c-fos mRNA expression is drastically reduced. Consistent with results of our previous study (Schmauss, 2000) , the blunted SKF-induced c-fos mRNA levels are still higher then the basal levels of either drug-naive or METH-pretreated double mutants (data not shown). METH pretreatment of D 2 /D 3 double mutants, however, leads to wildtype-like levels of c-fos mRNA in response to an SKF82958 challenge.
Blunted Fos protein expression in the PFC of D 1 agonist-treated D 2 and D 3 mutants
Although the expression of c-fos mRNA is a sensitive indicator of (acutely stimulated) neuronal activity, c-fos mRNA levels are not a perfectly reliable indicator for Fos protein levels. c-fos gene transcription is rapidly shut off (within minutes) after induction (Greenberg and Belasco, 1993) , and the rapid degradation of c-fos mRNA is a process that is tightly coupled to translation (Chen et al., 1994; Grosset et al., 2000) . In fact, a common feature of all immediate early genes is that their stability is profoundly increased when translational activity is low (Greenberg and Belasco, 1993) . Hence, regional c-fos mRNA levels may not correlate with corresponding protein levels. Therefore, as a more sensitive readout of the functional consequences of transcriptional c-fos induction, we performed a quantitative analysis of the expression of Fos immunoreactivity in neurons of the PFC.
The top panels of Figure 3 illustrate the anatomic topography of the subregions of the mouse PFC (IL, PL, and AC) (Fig. 3 , top left) and their neuronal cytoarchitecture revealed by NeuN immunolabeling of coronal sections taken 5.5 mm rostral to the interaural line (Fig. 3, top right) . The bottom panels of Figure 3 show the expression patterns of Fos immunoreactivity in coronal cryosections obtained from wild type. These sections were collected from fresh-frozen forebrains and processed in parallel. In contrast to mice receiving only saline, the administration of SKF82958 induces a robust expression of Fos immunoreactivity, which is distributed diffusely in all layers of the PFC and in a defined band of nuclei outlining the outermost extent of layer II. No obvious differences in the expression of SKF82958-stimulated In situ hybridization of c-fos mRNA expressed 60 min after SKF82958 (1 mg/kg) administration to drug-naive (saline-pretreated) wild type (WT ) and drug-naive and METH-pretreated homozygous D 2 /D 3 double mutants (DM ). METH (5 mg/kg) was administered 1 week before SKF administration. Sections were hybridized to a 35 S-labeled antisense riboprobe comprising 540 nucleotides of the mouse c-fos mRNA. Images on film were digitized using the MCID image analysis system and colorized uniformly to highlight c-fos signal intensities. Note the blunted SKF-stimulated c-fos mRNA expression in drug-naive double mutants that is completely reversed by METH pretreatment. M, Motor cortices; Str, striatum. Scale bar, 1 mm.
Fos immunoreactivity are evident between drug-naive and METH-pretreated wild type. Figure 4 compares the Fos immunoreactivity induced by SKF82958 in cryosections of the prelimbic subregion of the PFC obtained from fresh-frozen forebrains of drug-naive wild type and mutants that were processed in parallel. It also illustrates the Fos immunolabeling of neuronal nuclei of this subregion of drugnaive wild-type and mutant mice in thionin-counterstained microtome sections at 100ϫ magnification (Fig. 4, bottom) . Although the anatomic topography of the expression of Fos immunoreactivity is comparable with wild type, the quantity of Fosimmunoreactive nuclei is reduced in drug-naive D 2 and D 3 mutants (Fig. 4) . Consistent with our previous study , the blunted SKF-stimulated c-fos responses of the mutants are still substantially higher then corresponding responses seen in saline-treated mutants (data not shown).
Consistent with results of our previous study on c-fos mRNA expression in METH-pretreated wild type and mutants in the absence of a D 1 agonist challenge (Schmauss, 2000) , we found very low basal levels of Fos immunoreactivity in METH pretreated animals of all three genotypes (on average, in all subregions of the PFC, fewer than 10 labeled neuronal nuclei were detected in a single tissue section; data not shown). However, as shown in Figure 5 , compared with drug-naive mutants, METHpretreated mutants express substantially more Fos immunoreactivity in response to a challenge dose of SKF82958. Altogether, the results of the immunocytochemical studies shown in Figures 4 and 5 are in perfect agreement with the results of studies that measured c-fos mRNA (rather than protein) levels in the mutants (Fig. 2) (Schmauss, 2000) , and they suggest that the D 1 receptor responsiveness to agonist stimulation is substantially blunted in the PFC of drug-naive (but not METH-pretreated) D 2 and D 3 mutants. To ensure that these results are not attributable to differences in the numbers of prefrontal cortical neurons and to obtain a quantitative estimate of the magnitude of differences that are seen in Figures 4 and 5 , we used the optical fractionator to estimate the total number of Fos-immunoreactive neurons in layers II/III and V/VI of the IL, PL, and AC. Forty-micrometer- Top, Schematic illustration of the regional extent of the mouse PFC in a cross section taken 5.5 mm rostral to the interaural line and its cytoarchitecture visualized in a photomicrograph of an NeuN-immunolabeled section. Bottom, Expression of Fos immunoreactivity detected 60 min after saline or SKF82958 administration to wild type. In animals treated with saline, only a few nuclei express Fos immunoreactivity. SKF82958 induces a robust nuclear expression of Fos immunoreactivity in both the deep and superficial layers of the PFC. There is no obvious difference in the expression of SKF-stimulated Fos immunoreactivity between drug-naive and METH-pretreated wild type. M, Motor cortices; Str, striatum. Scale bar, 0.5 mm.
thick sections, processed to detect Fos immunoreactivity on a thionin-counterstained background, were subjected to this analysis (see Materials and Methods). The microscopic inspection of these sections revealed no differences between genotypes and treatment groups in the cytoarchitectures of the regions analyzed.
The stereological analysis of two laminar territories (layers II/III and V/VI) of each of the three subregions of the PFC (IL, PL, and AC) revealed no significant differences in the number of neurons and glia, as well as the volumes of the regions measured. Thus, the cellular packing density was similar across genotypes and treatment groups. Figure 6 summarizes the mean counts of Fos-immunoreactive neurons expressed as a percentage of the total number of neurons determined for each of the two laminar territories of each of the three prefrontal cortical subregions. In all targeted areas, no significant differences were found in the percentages of Fos-immunoreactive neurons counted in sections of drug-naive and METH-pretreated wild type. In the superficial (II/III) and deep (V/VI) layers of the IL cortex, however, the percentages of neurons expressing Fos immunoreactivity determined for both mutants were lower compared with wild type, and these reductions were slightly more severe in D 3 than in D 2 mutants (Fig. 6, top) (Fig. 6, middle) . Corresponding percentages calculated for METH-pretreated mutants, however, did not differ significantly from wild type. In METH-pretreated D 2 mutants, the percentages of Fos-immunoreactive neurons were 94% (layers II/III) and 93% (layers V/VI) of wild type, and they were significantly increased compared with corresponding percentages obtained from drug-naive D 2 mutants (layers II/III, p Ͻ 0.05; layers V/VI, p Ͻ 0.01). METH pretreatment of D 3 mutants led to a more modest increase in the percentages of neurons that express Fos immunoreactivity [80% (layers II/III) and 85% (layers V/VI) of wild type]. This increase, however, did not reach statistical significance when compared with drug-naive D 3 mutants.
The largest reduction in the expression of Fos immunoreactivity was found in the superficial and deep layers of the AC cortex of the mutants, and, similar to the PL cortex, the reduction was greater in D 2 than D 3 mutants (Fig. 6, bottom) . In drug-naive D 2 mutants, the mean percentage of neurons expressing Fos immunoreactivity was only 45% (layers II/III; p Ͻ 0.005) and 54% (layers V/VI; p Ͻ 0.005) of wild type, whereas in drug-naive D 3 mutants, the mean percentages were 62% (layers II/III; p Ͻ 0.01) and 68% (layers V/VI; p Ͻ 0.05) of wild-type mice. METH pretreatment of both mutants significantly increased the number of neurons expressing Fos immunoreactivity. In M ETHpretreated D 2 mutants, the mean percentages of neurons expressing Fos immunoreactivity slightly exceeded that of wild-type mice (layers II/III, 106%; layers V/VI, 108% of wild type), and they were significantly increased compared with the corresponding numbers determined for drug-naive D 2 mutants (layers II/III, p Ͻ 0.001; layers V/VI, p Ͻ 0.001). In METH-pretreated D 3 mutants, the mean percentages of Fos-immunoreactive neurons were 90% (layers II/III) and 85% (layers V/VI) of wild type. Although these estimates did not significantly differ from wild type, when compared with drug-naive D 3 mutants, they differed significantly only for numbers obtained from the superficial layers ( p Ͻ 0.05).
In summary, both D 2 and D 3 mutants exhibit a decreased agonist-stimulated D 1 receptor activity in the PFC. The magnitude of the long-term rescue of this blunted D 1 receptor activity by a single dose of METH was larger in D 2 than in D 3 mutants.
Spatial delayed alternation
Delayed alternation tasks are considered to be particularly sensitive in demonstrating working memory deficits after lesions of the PFC in all mammalian species (Markowitsch and Pritzel, 1977) . In rodents, this task is often performed in a T-maze (Moran, 1993) , a valuable tool for evaluating spatial working memory associated with prefrontal cortical function (Van Haaren et al., 1985) . Thus, because of the well documented role of prefrontal cortical D 1 receptors in the control of working memory (Williams and Goldman-Rakic, 1995; Zahrt et al., 1997) , we examined the performance of wild-type and mutant mice in a delayed alternation test performed in a T-maze. In contrast to the above study that relied on systemically administered D 1 agonists, the performance in the T-maze is dependent on D 1 receptors that are activated by physiological concentrations of synaptically released dopamine.
In a first series of experiments, homozygous D 3 mutants and their wild-type littermates were trained and tested in parallel as described in Materials and Methods. Wild type and D 3 mutants exhibited similar learning curves with near-chance level performance (40 -50% of correct arm entries) between days 5 and 12 of training (performed with 5 sec intertrial delays; data not shown), followed by a gradual improvement that reached a plateau of Ͼ70% correct arm entries on days 16 and 17 of the training (5 sec delay) (Fig. 7A) . Retention times in the holding box were then increased to 15, 20, and 30 sec delays. As can be seen in Figure 7A, the performance of wild-type mice remained stable at 15 and 20 sec, with no trend toward improved performance at these delay times, but deteriorated significantly ( p Ͻ 0.05) as the delay interval increased to 30 sec. The performance of D 3 mutants, however, deteriorated gradually with increasing memory load and differed significantly from wild type in tests with 15 ( p Ͻ 0.05) and 20 ( p Ͻ 0.01) sec delays (Fig. 7A) .
In a second series of experiments, homozygous D 2 mutants and their wild-type littermates were trained and tested in parallel. In this experiment, the learning curve and the test results obtained from wild type during the training period were in excellent agreement with results obtained from wild type tested in the first series involving D 3 mutants (data not shown). At days 16 and 17 of training, wild-type mice made Ͼ70% correct choices, and their performance remained stable with no trend of additional improvement at 15 and 20 sec delays, and, at 30 sec delay, their performance deteriorated significantly ( p Ͻ 0.01) (Fig. 7B) . In D 2 mutants, however, a significantly impaired performance is evident at all retention intervals, with increasing impairment at increasing delays (5 sec delay, p Ͻ 0.05; 15 sec delay, p Ͻ 0.01; 20 sec delay, p Ͻ 0.001).
In summary, drug-naive D 3 and D 2 mutants exhibited significant spatial working memory deficits. These deficits are not at- tributable to pronounced motivational impairments of the mutants. Both wild type and mutants exhibited "omission errors" (i.e., they visited the correct arm but did not take the food) only at the very beginning of the training but not subsequently (data not shown). Moreover, in all tests involving increasing delay periods, all mice started running immediately after the door of the holding box was opened, found the food, and ate it rapidly. Thus, mutants were able and motivated to perform the task, but their spatial working memory is reduced compared with wild type. Finally, although D 2 mutants run slightly slower than controls during training [a consequence of their impaired locomotor activity ], differences in running speed cannot account for the lack of improvement in their working memory performance at the end of the training (Aultman and Moghaddam, 2001) .
After baseline performance at all delay periods were established for the three drug-naive genotypes, all mice received a single injection of METH (5 mg/kg), and their working memory performance was monitored on days 1, 3, 5, and 6 after injection using the 5 sec delay paradigm. During this test period, the performance of wild-type mice tested in the first series fluctuated somewhat [percentage of correct arm entries: 71.4 Ϯ 7.4 (day 1); 65 Ϯ 6 (day 3); 70 Ϯ 5.4 (day 5); and 76.3 Ϯ 5.7 (day 6)] but did not statistically differ from corresponding results obtained from the same wild type before METH injection. The level of performance of D 3 mutants was decreased (percentage of correct arm entries: 61.4 Ϯ 8; 56.7 Ϯ 5.6; 57.1 Ϯ 4.7; and 61.4 Ϯ 8.6). This decrease, however, did not reach statistical significance. A slightly, but nonsignificantly, decreased performance level was also detected in the group of wild-type animals tested in the second series of experiments (65.8 Ϯ 4.6%; 71.3 Ϯ 3.5%; 71.3 Ϯ 4.4; and 65.7 Ϯ 6.1%). Interestingly, the performance of D 2 mutants gradually increased. On day 1 after METH, animals made 58.8 Ϯ 3.5% correct choices, a result almost identical to their drug-naive performance. On days 3, 5, and 6 after METH, however, their performance improved and reached 65.7 Ϯ 3.5, 62.5 Ϯ 5.6, and 65.0 Ϯ 3.3%, respectively, correct choices.
On days 7-12 after METH injection, animals were tested using the 15, 20, and 30 sec delay paradigms. Each delay period was tested twice (on 2 different days), and the means Ϯ SEM, shown in Figure 8 , represent all data obtained in these 2 d. For each delay period, the performance of all METH-pretreated controls did not differ from their drug-naive performance. The performance of METH-pretreated D 3 mutants also did not differ significantly from their drug-naive performance (Fig. 8 A) . METHpretreated D 2 mutants, however, significantly outperformed their drug-naive performance at 15 ( p Ͻ 0.01) and 20 ( p Ͻ 0.001) sec delays (Fig. 8 B) . In fact, the performance of METH-pretreated D 2 mutants recorded at 15, 20, and 30 sec delay periods differed neither from drug-naive nor METH-pretreated wild type. Thus, METH pretreatment rescues the working memory deficits of D 2 , but not D 3 , mutant mice.
The gradually improved performance of METH-pretreated D 2 mutants in the spatial working memory test, which peaked on day 8 after METH injection (and remained stable on the following days), suggested the possibility that SKF82958-stimulated c-fos responses of METH-pretreated mutants also increase gradually. However, results of Northern blots of frontal cortical RNA, shown in Figure 9 , revealed that the reversal of the blunted responsiveness of D 1 receptors to agonist stimulation is already evident 24 hr after METH injection. Thus, in D 2 mutants, the onset of the rescued agonist-stimulated D 1 receptor activity and the onset of rescued cognitive performance are separated by a delay of ϳ7 d. This time may be needed to reactivate neuronal circuitries that are critically involved in spatial working memory.
DISCUSSION
The present study shows blunted prefrontal cortical c-fos responses to D 1 agonist stimulation in mice deficient for D 2 and D 3 receptors and an impaired performance of these mutants in a spatial working memory task.
Previous work from our laboratory has shown that either a single dose of METH or a full D 1 agonist leads to a long-term (as much as 2 weeks) reversal of the blunted D 1 agonist-stimulated c-fos expression in D 2 and D 3 mutants (Schmauss, 2000) . Whereas the present quantitative analysis of expression of Fos immunoreactivity in the PFC of drug-naive and METH-pretreated D 2 and D 3 mutants confirmed these previous findings, it also revealed a number of important quantitative differences between both mutants. Reductions in the neuronal expression of Fos immunoreactivity in drug-naive mutants are evident in all regions examined. They are more significant in the AC than in the PL cortex, and they are only modest in the IL cortex. In the superficial and deep layers of the AC or PL cortices, however, the reduced expression of Fos immunoreactivity is more pronounced in D 2 than D 3 mutants (although reductions in the IL cortex of D 3 mutants exceeded that estimated for D 2 mutants). Whereas METH pretreatment resulted in an increased number of neurons that expressed Fos immunoreactivity in response to D 1 agonist stimulation in both mutants, the rescue is greatest in the AC and PL cortices relative to the IL cortex, and the rescue is greater in D 2 than in D 3 mutants. In fact, D 1 agonist-stimulated c-fos responses in the AC and PL subregions of the PFC are indistinguishable from wild type only in METH-pretreated D 2 mutants.
It is highly unlikely that differences in the behavioral state of SKF82958-treated drug-naive and METH-pretreated animals contributed to the differences seen in c-fos responses in the PFC. All genotypes exhibit an increased horizontal locomotor activity in response to SKF, and the predominant locomotor response of drug-naive animals is an oral stereotypy (sniffing, nibbling, and licking). Quantitatively, this stereotypic response does not differ between wild type and D 3 mutants, but it is significantly enhanced in D 2 mutants (Glickstein and Schmauss, 2001) . This is unlikely to be attributable to decreased D 1 receptor activation in the PFC because both D 2 and D 3 mutants show significantly reduced prefrontal cortical c-fos responses to SKF. In METH-pretreated animals, the response to SKF is no longer predominantly stereotypic but rather characterized by increased horizontal locomotion (running) that appeared indistinguishable between genotypes.
Blunted activity of D 1 receptors in the PFC of D 2 and D 3 mutants is also evident when the performance of these mutants in a delayed alternation test, a spatial working memory task, is compared with wild type. The performance of D 2 mutants is impaired at all delay periods with increasing impairment at increasing delays. In comparison, the performance of D 3 mutants is less impaired, and D 3 mutants are similar to wild type at the shortest delay (5 sec). These differences parallel the differences between both mutants in the magnitude of the blunted D 1 -agonist-stimulated c-fos responses in the AC and PL subregions of the PFC. Moreover, METH pretreatment affects the impaired working memory of both mutants differently. It completely restores wild-type-like performance levels in D 2 mutants, but it does not alleviate the working memory deficits of D 3 mutants. Interestingly, the stereologic analysis of D 1 agonist-stimulated c-fos responses revealed that, in AC and PL, c-fos responses of METH-pretreated D 3 mutants remain submaximal. The correlation between D 1 agonist-induced c-fos expression levels and the levels of performance in the spatial working memory task suggest that the sustained improvement of spatial working memory in METH-pretreated D 2 mutants is attributable to D 1 receptormediated mechanisms. However, our study has only established a correlation between the different magnitudes of prefrontal cortical c-fos responses to D 1 agonist stimulation and the different levels of performance in working memory tasks. Direct evidence that these c-fos responses are necessary for working memory or, alternatively, that some D 1 receptor function is necessary for spatial working memory but independent of c-fos expression levels is still lacking.
The finding of spatial working memory deficits of mice deficient for D 2 and D 3 receptors is consistent with results of a recent study showing that chronic treatment of monkeys with neuroleptic drugs (that block D 2 -like receptors) impairs their performance in working memory tests (Castner et al., 2000) . We also found that chronic (but not acute or subacute) administration of neuroleptic drugs to wild-type mice decreases their c-fos responses to D 1 agonist stimulation (S. B. Glickstein and C. Schmauss, unpublished observation). Moreover, several findings shown in Figures 7 and 8 illustrate clearly that the performance of mice in the T-maze reflects their working memory capacity: (1) the performance of wild type in the delayed alternation task is stable up to 20 sec retention intervals, and the accuracy of their performance is inversely proportional to retention time; (2) during the entire test period, the performance of wild type and mutants remained at a submaximal level (indicating that no "overtraining" occurred that would have required the implementation of longer retention times); (3) the impaired performance of drug-naive D 2 and D 3 mutants is also sensitive to delay periods, i.e., a gradually decreased performance was detected at increasing delay; and (4) no evidence for a decreased motivation of the mutants to perform the test was obtained. The weight of the present evidence therefore suggests that the spatial working memory deficit of D 2 and D 3 mutants is attributable to their decreased prefrontal cortical D 1 receptor activity. However, direct proof that the working memory deficits described here are attributable to decreased D 1 receptor activity remains to be provided. Delay periods are indicated on the abscissa, and the dashed line across the bars at 50% correct arm entries indicates chance performance. Each delay period was tested twice, and the means of both days were statistically compared (ANOVA) between genotypes and treatment groups. Statistical differences are indicated on top of the corresponding bars. In both series of experiments and for all three delay periods, no statistical differences were found between drug-naive and METH-pretreated wild type (wild type-D 3 series, p ϭ 0.09, p ϭ 0.32, and p ϭ 0.22 at 15, 20, and 30 sec delay, respectively; wild type-D 2 series, p ϭ 0.09, p ϭ 0.10, and p ϭ 0.32 at 15, 20, and 30 sec delay, respectively).
An unexpected finding of the present study is that, in contrast to METH-pretreated D 2 mutants, METH-pretreated D 3 mutants show only a submaximal rescue of prefrontal c-fos responses to D 1 agonist stimulation, and METH pretreatment does not rescue their spatial working memory deficit. The reasons for the resistance of D 3 mutants to METH pretreatment are presently unknown. It is possible that the inactivation of D 3 receptors does not only lead to blunted prefrontal cortical D 1 receptor responses to agonist stimulation but that D 3 receptors also play a direct role in the control of working memory, a role that would be abolished in the D 3 (but not D 2 ) mutants. It is also possible that different mechanisms lead to the similarly blunted D 1 receptor activity in both mutants and that METH predominantly affects those mechanisms that are responsible for the phenotype detected in D 2 mutants. For example, we reported recently that D 2 , but not D 3 , mutants exhibit decreased G-protein activation in response to D 1 agonist stimulation and that this G-protein activation is differently affected by inhibition of phosphatases 1/2A and 2B in both mutants. The decreased SKF82958-stimulated G-protein activation of D 2 mutants is completely reversed by METH pretreatment, but the abnormal sensitivities to phosphatase inhibitions are unaffected by METH pretreatment of both mutants (Hsiung et al., 2001) .
How can a single, low dose of METH exert the long-lasting effects described here? METH has many complex actions, and not all of its targets may yet be known. For example, at the level of neuronal circuitries, METH could have prolonged stimulatory effects on dopamine synthesis in midbrain dopaminergic neurons and, thus, enable increased activation of projection areas (including the PFC) during stimulation. This hypothesis is consistent with the observation that a single dose of amphetamine leads to a sustained increase in electrically evoked release of dopamine in the forebrain (Vanderschuren et al., 1999) . The long-lasting effects of METH could also be mediated by mechanisms that operate at the cellular level and that involve, for example, sustained decreases in the kinetics of agonist-provoked receptor internalization. Such decreases would increase the size of the receptor pool available for agonist stimulation. As mentioned above, we have preliminary evidence supporting the hypothesis that D 1 receptors expressed in the neocortex of D 2 mutants are hyperphosphorylated, suggesting that a large proportion of these receptors are not available for high-affinity agonist binding (Hsiung et al., 2001) . When these mutants are pretreated with M ETH, however, the amount of agonist-stimulated G-protein activation increases significantly, and we are currently investigating whether M ETH pretreatment restores the normal phosphorylation state of the receptor expressed in the mutants.
Finally, in view of the potential clinical importance of the present findings that suggest that the chronic treatment of schizophrenic patients with typical neuroleptic drugs (that block the D 2 class of dopamine receptors) worsens their cognitive deficits and that the selective blockade of either D 2 or D 3 receptors would have the same effect, more research is needed to elucidate the different mechanisms that maintain and disrupt the normally balanced activities of D 1 , D 2 , and D 3 receptors in vivo. Figure 9 . SKF82958-stimulated c-fos mRNA expression detected 1-7 d after METH pretreatment. Northern blot of frontal cortical c-fos mRNA expressed 60 min after injection of SKF82958 (1 mg/kg) in drug-naive (lanes marked SK F ) and M ETH-pretreated D 2 (D2 Ϫ/Ϫ) and D 3 (D3 Ϫ/Ϫ) mice. Lanes marked 1, 3, 5, and 7 illustrate SK F-stimulated c-fos mRNA levels detected 1, 3, 5, and 7 d, respectively, after M ETH (5 mg / kg) pretreatment.
